

Posting Date: April 15, 2021

Closing Date: April 25, 2021 11:30 a.m. ET

Reference Number: 21-031806

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – Service Agreement

The Genitourinary Malignancies Branch focuses on investigating the biology of genitourinary cancers, developing new strategies for treating those cancers, and evaluating these new therapeutic approaches through science-driven clinical research. These clinical trials investigate novel approaches in immunotherapy, hormonal therapy, chemotherapy combinations, and small-molecule targeted therapy.

The National Cancer Institute plans to purchase Gold Service Agreement for (SN: VP1732N1027) Vectra Polaris from Akoya Biosciences. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine if the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on April 25, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

Akoya is the only source of the scanner that is proprietary to their company and has been taking care of it from the time it was purchased while under the original maintenance agreement that came with the purchase.

Attached Documents:

SF18

Statement of Work

FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request